Protara Therapeutics (TARA) Assets Average (2014 - 2026)
Protara Therapeutics (TARA) posted quarterly Assets Average of $200.7 million for Q1 2026, up 14.68% year-over-year from $175.0 million in Q1 2025, and up 13.35% quarter-over-quarter from $177.1 million in Q4 2025.
Protara Therapeutics (TARA) Assets Average (2014 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Assets Average for 13 consecutive years, with $200.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 14.68% year-over-year to $200.7 million; the TTM figure through Mar 2026 stood at $200.7 million (up 14.68% YoY), while the FY2025 annual figure was $195.5 million, up 50.12% from the prior year.
- Assets Average improved to $200.7 million in Q1 2026 per TARA's latest filing, from $177.1 million in the prior quarter.
- Across five years, Assets Average topped out at $200.7 million in Q1 2026 and bottomed at $73.5 million in Q1 2024.
- Historically, Assets Average has averaged $132.6 million across 5 years, with a median of $137.8 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 39.5% — and 2025, when it soared 137.96%.
- Protara Therapeutics' Assets Average stood at $130.9 million in 2022, then slumped by 36.07% to $83.7 million in 2023, then jumped by 64.58% to $137.8 million in 2024, then climbed by 28.51% to $177.1 million in 2025, then advanced by 13.35% to $200.7 million in 2026.
- Business Quant data shows TARA's Assets Average at $200.7 million in Q1 2026, $177.1 million in Q4 2025, and $150.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 184.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 184.01 Mn |
| Mar 31, 2026 | 200.70 Mn |
| Dec 31, 2025 | 177.05 Mn |
| Sep 30, 2025 | 150.78 Mn |
| Jun 30, 2025 | 162.75 Mn |
| Mar 31, 2025 | 175.01 Mn |
| Dec 31, 2024 | 137.77 Mn |
| Sep 30, 2024 | 97.87 Mn |
| Jun 30, 2024 | 84.89 Mn |
| Mar 31, 2024 | 73.54 Mn |
| Dec 31, 2023 | 83.71 Mn |
| Sep 30, 2023 | 91.80 Mn |
| Jun 30, 2023 | 100.77 Mn |
| Mar 31, 2023 | 109.85 Mn |
| Dec 31, 2022 | 130.94 Mn |
| Sep 30, 2022 | 151.74 Mn |
| Jun 30, 2022 | 158.07 Mn |
| Mar 31, 2022 | 166.93 Mn |
| Dec 31, 2021 | 176.65 Mn |
| Sep 30, 2021 | 184.79 Mn |